Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies

Abstract

During 44 weeks of as-needed treatment, ruxolitinib cream demonstrated effective disease control and tolerability; low ruxolitinib plasma concentrations alongside safety findings reflecting known risk factors suggest physiologically meaningful systemic Janus kinase inhibition is highly unlikely.